Clayton Partners’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.74M Sell
23,142
-70
-0.3% -$11.7K 2.43% 13
2026
Q2
$4.4M Buy
23,212
+68
+0.3% +$12.8K 2.89% 13
2026
Q1
$4.56M Buy
23,144
+74
+0.3% +$14.3K 3.32% 11
2025
Q4
$4.24M Sell
23,070
-256
-1% -$44.9K 3.06% 11
2025
Q3
$3.58M Sell
23,326
-48
-0.2% -$7.26K 2.71% 17
2025
Q2
$3.27M Sell
23,374
-2,445
-9% -$343K 2.74% 15
2025
Q1
$3.8M Buy
25,819
+2,847
+12% +$412K 3.3% 10
2024
Q4
$3.01M Sell
22,972
-142
-0.6% -$19.9K 2.08% 21
2024
Q3
$3.6M Sell
23,114
-157
-0.7% -$25.3K 2.59% 17
2024
Q2
$3.63M Buy
23,271
+4,834
+26% +$727K 2.92% 13
2024
Q1
$2.5M Buy
+18,437
New +$2.44M 2.12% 22

Other funds holding AZN

Clayton Partners's AZN Position: Q3 2026 in Review

Clayton Partners reduced its AstraZeneca (AZN) stake by 0.3% in Q3 2026, selling an estimated $11.7K and leaving 23,142 shares worth $3.74M. The position accounts for 2.43% of the portfolio, ranked #13.

Clayton Partners first reported a position in AZN in Q1 2024 and has held it in 11 quarters since. The position peaked at $4.56M in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Clayton Partners held 23,142 shares of AstraZeneca worth $3.74M as of Q3 2026.
  • Clayton Partners sold 70 AstraZeneca shares in Q3 2026, an estimated $11.7K.
  • AstraZeneca made up 2.43% of Clayton Partners's portfolio in Q3 2026, its #13 holding.
  • Clayton Partners first reported a position in AstraZeneca in Q1 2024 and has held it in 11 quarters since.
  • Clayton Partners's AstraZeneca position peaked at $4.56M in Q1 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Clayton Partners's 13F filing for Q3 2026, filed 16 Nov 2026.